Moch, H

Menon, S; Moch, H; Berney, D M; Cree, I A; Srigley, J R; Tsuzuki, T; Compérat, E; Hartmann, A; Netto, G; Rubin, Mark A; Gill, A J; Turajlic, S; Tan, P H; Raspollini, M R; Tickoo, S K; Amin, M B (2023). The WHO 2022 classification of penile and scrotal cancers: updates and evolution. Histopathology, 82(4), pp. 508-520. Wiley 10.1111/his.14824

Berney, D M; Cree, I; Rao, V; Moch, H; Srigley, J R; Tsuzuki, T; Amin, M B; Comperat, E M; Hartmann, A; Menon, S; Netto, G J; Rubin, M A; Turajlic, S; Raspollini, M R; Tickoo, S K (2022). An Introduction to the WHO 5th Edition 2022 Classification of Testicular tumours. Histopathology, 81(4), pp. 459-466. Wiley 10.1111/his.14675

Pauli, C; Moch, H; Rubin, Mark Andrew (2017). [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models]. Der Pathologe, 38(Suppl 2), pp. 160-168. Springer 10.1007/s00292-017-0346-1

Huber, F; Montani, Matteo; Sulser, T; Jaggi, Rolf; Wild, P; Moch, H; Gevensleben, H; Schmid-Maurer, Christine; Wyder, Stefan; Kristiansen, G (2015). Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer-what has gone wrong? A blueprint for the way forward in biomarker studies. British journal of cancer, 112(1), pp. 140-148. Nature Publishing Group 10.1038/bjc.2014.588

von Moos, R; Seifert, B; Simcock, M; Goldinger, S M; Gillessen, S; Ochsenbein, A; Michielin, O; Cathomas, R; Schläppi, M; Moch, H; Schraml, P H; Mjhic-Probst, D; Mamot, C; Schönewolf, N; Dummer, R; Swiss Group for Clinical Cancer Research, (SAKK) (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of oncology, 23(2), pp. 531-6. Oxford: Oxford University Press 10.1093/annonc/mdr126

Schmitt, A M; Schmid, S; Rudolph, T; Anlauf, M; Prinz, C; Klöppel, G; Moch, H; Heitz, P U; Komminoth, P; Perren, A (2009). VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocrine-related cancer, 16(4), pp. 1219-27. Bristol: BioScientifica Ltd. 10.1677/ERC-08-0297

Langer, I; Guller, U; Hsu-Schmitz, S F; Ladewig, A; Viehl, C T; Moch, H; Wight, E; Harder, F; Oertli, D; Zuber, M (2009). Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. European journal of surgical oncology EJSO, 35(8), pp. 805-13. Amsterdam: Elsevier 10.1016/j.ejso.2008.09.006